Chromosome 1 abnormalities in newly diagnosed elderly multiple myeloma patients treated with novel therapies. by Caltagirone, S et al.
08 January 2022
AperTO - Archivio Istituzionale Open Access dell'Università di Torino
Original Citation:
Chromosome 1 abnormalities in newly diagnosed elderly multiple myeloma patients treated with novel therapies.
Terms of use:
Open Access
(Article begins on next page)
Anyone can freely access the full text of works made available as "Open Access". Works made available under a
Creative Commons license can be used according to the terms and conditions of said license. Use of all other works
requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.
Availability:
This is the author's manuscript






This is an author version of the contribution published on: 
Questa è la versione dell’autore dell’opera: 
 [Haematologica. 2014 Oct;99(10):1611-7. doi: 10.3324/haematol.2014.103853. 
Epub 2014 Jul 11.] 
The definitive version is available at: 









Chromosome 1 abnormalities in elderly 
patients with newly diagnosed multiple 
myeloma treated with novel therapies 



































Multiple myeloma is a plasma cell disorder characterized by malignant plasma cell infiltration in 
the bone marrow, serum and/or urine monoclonal protein and organ damage. The aim of this study 
was to investigate the impact of chromosome 1 abnormalities in a group of elderly patients (>65 
years) with newly diagnosed multiple myeloma enrolled in the GIMEMA-MM-03-05 trial and 
treated with bortezomib, melphalan and prednisone or bortezomib, melphalan, prednisone and 
thalidomide followed by bortezomib and thalidomide maintenance. We also evaluated the link 
between chromosome 1 abnormalities and other clinical, genetic and immunophenotypic features by 
a multivariate logistic regression model. Interphase fluorescence in situ hybridization on 
immunomagnetically purified plasma cells and bone marrow multiparameter flow cytometry were 





 immunophenotype of bone marrow plasma cells were independent risk factors for 
overall survival in elderly patients with newly diagnosed multiple myeloma. Moreover, a 
detrimental effect of thalidomide, even when administered in association with bortezomib, was 
observed in patients with abnormal chromosome 1 as well as in those with 17p deletion, while the 
benefit of adding thalidomide to the bortezomib-melphalan-prednisone regimen was noted in 




 bone marrow plasma cell immunophenotype. This 
trial was registered at www.clinicaltri-als.gov as #NCT01063179. 
Introduction 
Multiple myeloma (MM) is a plasma cell disorder characterized by the expansion of clonal plasma 
cells in the bone marrow (>10%), monoclonal immunoglobulins (Ig) in serum and/or urine and 
organ damage. Two-thirds of patients with MM are older than 65 years. In Europe, approved 
therapy for elderly patients or patients not eligible for transplantation is currently based on 
melphalan (M) and prednisone (P) with thalidomide (T) or bortezomib (V). Recent studies show 
that lenalidomide, in association with MP or dexamethasone, is a valid alternative.
1
 Despite the 
introduction of novel agents in clinical practice, the outcome differs greatly among patients and new 




Multiparameter flow cytometry is widely used to characterize bone marrow plasma cells (BMPC) 
and its impact on defining patients’ prognosis has been investigated by several authors.
3–7
 
Multiparameter flow cytometry is currently the main tool for evaluating minimal residual disease
6
 
during follow-up, while, at diagnosis, cytogenetic abnormalities represent powerful prognostic 
factors together with the International Staging System (ISS) stage.
8–12
 
Interphase fluorescence in situ hybridization (iFISH) enables identification of the most important 
genetic aberrations, such as deletion of RB1 [del(13)], P53 [del(17p)], 1p [del(1p)], gain(1q) and 
IGH translocations.
13,14
 In a previous study
15
 two groups of MM patients with different prognoses 
were identified: the “high-risk group” was characterized by the presence of at least one among 
del(17p), t(4;14)(p16;q32) and t(14;16)(q32;q23), while the “standard-risk group” was 
characterized by the absence of any of the aforementioned abnormalities. 
Several other chromosomal aberrations have been investigated and gain(1q) has been identified as 
one of the most recurrent genetic events
15
 (>50%). Gain(1q) has recently been included in a new 
cytogenetic classification based on iFISH analysis
16
: “adverse iFISH”, defined by the presence of 
one or more of the following aberrations: gain(1q), t(4;14), t(14;16), t(14;20)(p12-p21;q32), and 
del(17p), and “favorable iFISH”, characterized by the absence of these cytogenetic abnormalities 
and/or by the presence of hyperdiploidy, t(6;14)(p12-p21;q32) or t(11;14)(q13;q32). Del(1p) is 
quite a rare event (<10%) and is considered an adverse prognostic factor in young patients.
15,16
 The 
relevance of chromosome 1 (chr1) abnormalities has been reported in several studies: Shaughnessy 
et al. defined a 70-gene high-risk signature, in which 30% of genes mapped to chr1, suggesting the 
significant poor prognostic impact of gain(1q) and del(1p).
17
 Moreover, CKS1B overexpression at 
1q21 and its involvement in aggressive disease have been described.
18
 Leone et al. focused on 
CDKN2C deletion, at 1p32.3, which strongly affects cell-cycle regulation and MM pathogenesis.
19
 
Despite the considerable number of molecular and clinical studies on gain(1q), del(1p) or both
20–25
, 
the real role of chr1 abnormalities in MM remains a matter of debate. As far as gain(1q) is 
concerned, the poor prognostic impact of this aberration has been demonstrated in several series of 
patients: (i) in newly diagnosed patients, enrolled in the CMG2002 trial, treated with high-dose 
chemotherapy and autologous stem cell transplantation
26
; (ii) in patients with recurrent disease, 
treated with lenalidomide and dexamethasone
27




In recent investigations of the efficacy of thalidomide-based regimens in both newly diagnosed and 
relapsed/refractory MM patients carrying gain(1q21), it was found that thalidomide is not capable 
of overcoming the adverse influence of gain(1q) on survival.
29,30
 
This retrospective study examines the clinical impact of chr1 aberrations, other common 
cytogenetic abnormalities and plasma cell immunophenotype in a large series of elderly patients 
with newly diagnosed MM enrolled in a phase III randomized trial comparing VMP versus VMPT 
followed by VT maintenance (VMPT-VT). 
Methods 
Patients 
Between 2006 and 2009, 511 elderly (>65 years), untreated MM patients from 61 Italian 
Hematology Centers were enrolled in a phase III randomized clinical trial comparing VMP versus 
VMPT-VT
31,32
. Patients gave written, informed consent before entering the study, which was 
performed according to the Declaration of Helsinki (Ethics Committee approval number 
163/0057512). Bone marrow samples (n=399) were sent to our laboratory for centralized analysis 
and underwent multiparameter flow cytometry. Of the 399 samples, 376 were purified for routine 
iFISH analysis. The amount of BMPC allowed evaluation of chr1 abnormalities in 278/376 patients. 
Immunophenotype 
Four-color multiparameter flow cytometry was performed using CD38 APC, CD138 FITC, CD20 
APC, CD45 PerCP, CD19 PerCP-Cy5.5, cytoplasmic κ FITC and λ PE (BD Biosciences), CD117 
PE and CD56 PE (Caltag Laboratories) monoclonal antibodies. A FACSCalibur flow cytometer 
was used for data acquisition, and CELL Quest Pro Software for analysis. An antigen was 
considered positive when >30% of BMPC expressed it on the cell surface. 
Bone marrow plasma cell sorting 
BMPC were enriched using anti-CD138-coated magnetic microbeads and an AutoMACS Pro 
separator (Miltenyi Biotech) following the manufacturer’s instructions, then fixed in Carnoy’s 
solution. Purity was assessed by multiparameter flow cytometry (plasma cell purity always 
exceeded 90%). 
Interphase fluorescence in situ hybridization 
iFISH was performed according to the manufacturer’s instructions. Probes for 1p32, RB1 (on 
13q14), and P53 (on 17p13.1) deletions; 1q21 gain and t(11;14)(q13;q32), t(4;14)(p16;q32), 
t(14;16)(q32;q23) were purchased from Cytocell. Nuclei were analyzed using an Olympus BX41 
fluorescent light microscope. Two hundred BMPC nuclei from each sample were scored. The cut-
off levels for positive values were the means plus three standard deviations of BMPC from 15 
healthy donors, and were adjusted to 15% for IGH translocations and 10% for deletions/gains. Chr 
1 patterns were considered positive or negative as shown in Figure 1C,D. 
 
 
Figure 1. Abnormal chr1: Kaplan Meier curves and iFISH patterns. Clinical outcome of 
patients carrying abnormal chr1 [del(1p) and/or gain(1q)]: (A) Kaplan-Meier curve for PFS; 
(B) Kaplan-Meier curve for overall survival; (C) iFISH patterns for del(1p): two green signals 
in plasma cells carrying 1q gain 
Statistical analysis 
The primary end-points were overall survival, defined as the time from study entry to death from 
any cause, and progression-free survival, defined as the time from study entry until documented 
disease progression or death from MM. Patients still alive and free of disease progression were 
censored at the date of last contact. 
For univariate analyses, overall and progression-free survival curves were estimated by the Kaplan-
Meier method and compared using the log-rank test. Overall and progression-free survival were 
also analyzed by the Cox proportional hazard model comparing, by the Wald test, chemotherapy 
(VMPT-VT versus VMP), age at diagnosis (>75 versus ≤75 years), ISS stage (III versus II versus 
I), abnormal chr1 [del(1p) and/or gain(1q)], del(13), del(17p), t(11;14), [t(4;14) and/or t(14;16)] 
(any versus none), CD19, CD20, CD45, CD56 and CD117 expression on ≥30% versus <30% of 




 combination (any versus none). The effect of the same risk 
factors on overall survival was assessed using a multivariate Cox model. A multivariate binary 
logistic regression model was used to test age, ISS, iFISH abnormalities (independent variables) as 
risk factors for the onset of abnormal chr1 (dependent variable). 
Patients’ characteristics were tested using the Fisher exact test for categorical variables and the 
Mann-Whitney test for continuous ones. All reported P-values are two-sided, at the conventional 
5% significance level. Data were analyzed as of April 2014 by SPSS 21.0.0 and R 2.15.2 software. 
Results 
The baseline characteristics of the enrolled patients (n=511) were described in a previous report.
31
 
At the current median follow-up of 54 months from the start of therapy (range, 1 to 80 months), the 
median progression-free survival is 25 months and the median overall survival has not yet been 
reached (50.6%). 
Chr1 iFISH analysis was performed in 278 patients, based on sample availability. These patients 
showed the same baseline characteristics as those in whom chr1 abnormalities were not analyzed 
(Online Supplementary Table SX). 
The frequencies of del(13), del(17p), t(11;14), t(4;14), t(14;16) and high-risk chromosomal 
abnormalities have already been reported by Palumbo et al.
31
 and are summarized in Table 1 










Table 1. Baseline frequency of chromosomal abnormalities in BMPC detected by iFISH. 
 
 
The frequency of chr1 abnormalities was higher in the group treated with VMP than in the group 
treated with VMPT-VT; this was due to an asymmetric distribution of gain(1q) between the two 
groups, whereas del(1p) was equally distributed, (Table 1). 
Multivariate logistic regression analysis was used in order to identify protective/risk factors for the 
presence of an abnormal chr1 and included age, ISS stage and iFISH chromosomal abnormalities 
[del(13), del(17p), t(11;14) and t(4;14)/t(14;16)] (Table 2, panel A). Del(13) and t(4;14)/t(14;16) 
were found to be independent risk factors of borderline significance [odds ratio (OR), 1.80; 95% 
confidence interval (95% CI), 0.95–3.43; P=0.074 and OR, 2.06; 95% CI, 1.00–4.27; P=0.051, 
respectively) while t(11;14) showed a strong protective role (OR, 0.15; 95% CI, 0.05–0.47; 
P=0.001). Immunophenotypic features were also tested by logistic regression analysis, but they did 





















Table 2. Multivariate regression models. 
 
 
The associations of chr1 abnormalities with cytogenetic and immunophenotypic features are 
presented in Online Supplementary Table SZ and Online Supplementary Figure S2). 
Figure 1 shows Kaplan-Meier curves for progression-free survival and overall survival according to 
abnormal chr1 status, highlighting the significant negative impact of such abnormalities on 
progression-free survival (P=0.009). The presence of chr1 abnormalities appears to have an unusual 
effect on overall survival, with the impact varying over time, suggesting that this cytogenetic 
feature should be considered as a time-dependent variable. This hypothesis was confirmed by the 
Shoenfeld test and, subsequently, Cox analyses were carried out with a time-dependent 
methodology. 
Del(13), del(17p), IGH translocations and high-risk cytogenetics did not significantly affect overall 
or progression-free survival of enrolled patients (data not shown), except for t(11;14) which 
displayed a borderline protective role for overall survival [hazard ratio (HR), 0.35; 95% CI, 0.12–
1.02; P=0.053]. 
The immunophenotypic features of BMPC are shown in Online Supplementary Table SY and were 
equally distributed between the two therapeutic groups. Expression of CD19, CD20, CD45, CD56, 
CD117 and cytoplasmic k or λ Ig-light-chains did not significantly influence either overall survival 
or progression-free survival (data not shown). Interestingly, through analysis of several antigen 




 immunophenotype as forming a 
particular risk category for overall survival (HR, 3.51; 95% CI, 1.20–10.31; P=0.022), but not for 
progression-free survival. This combination was present in 10.3% of all patients and was equally 
distributed between the VMP and VMPT-VT treatment groups (9.9% versus 10.6%; P=0.871). 
Based on univariate Cox analyses, a multivariate Cox regression model for overall survival was 





phenotype (Table 2, panel B). Independent predictors for a worse overall survival were age (HR, 





 immunophenotype (HR, 2.62; 95% CI, 1.23 to 5.58; P=0.012). 
Differential effect of thalidomide 
Taking into account that chr1 abnormalities were not equally distributed between the two 
therapeutic arms, abnormal chr1 and all the other variables were also analyzed separately in order to 
test for a potential adverse interaction with the thalidomide regimen (Table 3). Abnormal chr1 had a 
significant adverse impact in the VMPT-VT arm (HR, 3.08; 95% CI, 1.04–9.14; P=0.042), which 
was not apparent in the VMP arm (HR, 2.61; 95% CI, 0.83–8.20; P=0.102). Moreover, our data 
suggest that thalidomide impairs survival in patients carrying del(17p) (VMPT-VT arm: HR, 4.28; 
95% CI, 1.59–11.54; P=0.004 and VMP arm: HR, 1.11; 95% CI, 0.34–3.66; P=0.866). Conversely, 
thalidomide had a protective role in patients with CD19
+
 (VMP arm: HR, 3.89; 95% CI, 1.13–





BMPC (VMP arm: HR, 5.00; 95% CI, 1.15–21.78; P=0.032 and VMPT-VT arm: HR, 2.33; 95% 
CI, 0.44–12.32; P=0.320) and advanced ISS stage (ISS III versus I in the VMP arm: HR, 2.56; 95% 
CI, 1.36–4.82; P=0.004 and ISS III versus I in the VMPT-VT arm: HR, 1.65; 95% CI, 0.86–3.14; 
P=0.129). Age significantly affected overall survival in both arms (VMP arm: HR, 2.29; 95% CI, 
1.04–5.04; P=0.040 and VMPT-VT arm: HR, 4.53; 95% CI, 1.84–11.14; P=0.001). No significant 
differences were found between the two arms for the other cytogenetic abnormalities or 
immunophenotypes. 
 
Table 3. Univariate Cox analyses for overall survival: impact of baseline clinical and 




The introduction of novel agents in the clinical management of MM has led to the need for new risk 
predictors and although cytogenetic abnormalities represent strong prognostic factors, their real role 
in risk prediction is still a matter of debate. 
Del(13), del(17p), IGH translocations and high-risk chromosomal abnormalities did not show a 
significant impact on overall survival or progression-free survival of patients enrolled in the VMP 
versus VMPT-VT trial. This finding confirms and emphasizes the already reported beneficial role 
of bortezomib, which seems to overcome the negative impact of poor prognostic cytogenetic 
features.
29,31,33
 This was demonstrated not just in the study by Palumbo et al.,
31
 but also in the 
bortezomib-based trial by Harousseau et al.,
34
 which showed a similar progression-free survival 
between cytogenetically defined high-risk and standard-risk patients. Moreover, the Spanish VISTA 
trial
35
, comparing MP and VMP, showed that, in the VMP subgroup, there was no statistically 
significant difference in overall survival between high-risk and standard-risk patients. In line with 
all these findings, in our series of patients, del(17p), t(4;14) and t(14;16) did not have any impact on 
clinical outcome, even at the present follow-up. Indeed, a very recent paper from the Mayo Clinic
36
 
set new guidelines for MM treatment defining that: (i) patients with t(4;14) should receive 
bortezomib as part of induction and maintenance treatment for at least 1 year, in order to overcome 
the adverse impact of t(4;14) on overall survival; (ii) high-risk patients should receive lenalidomide, 
bortezomib and dexamethasone; (iii) standard-risk patients can be treated with low-toxicity 
regimens incorporating lenalidomide and low-dose dexamethasone. 
The clinical impact of chr1 abnormalities has so far been evaluated in heterogeneous groups of MM 
patients, treated with different therapeutic regimens
17–19,26–28,37
 and gain(1q) and del(1p) were 
considered so closely related that it is hard to determine their distinct clinical impact.
15,38
 In this 
study we referred only to “abnormal chr1”, defined as del(1p) and/or gain (1q), which was present 
in 50.7% of patients: its poor prognostic impact on overall survival and progression-free survival 
was more significant than that of del(1p) or gain(1q) considered separately (data not shown). 
Logistic regression analysis identified del(13) and t(4;14)/t(14;16) as risk factors of borderline 
significance for the presence of abnormal chr1, while t(11;14) emerged as a strong protective factor. 
These data (Table 2, panel A) do not only describe an association, but they highlight a cause-effect 
relationship between the presence/absence of some chromosomal abnormalities and the onset of an 
abnormal chr1. 
Del(1p) was equally distributed between the two treatment groups, while gain(1q) was more 
frequent in the VMP treatment group than in the VMPT-VT group. This bias may have occurred 
since patients were not randomized in the light of cytogenetic characteristics. Chr1 abnormalities 
were more frequent in the VMP arm and we expected to observe a major negative impact on 
survival in this group. Interestingly, however, a significant negative impact on overall survival was 
observed only in the VMPT-VT arm, as shown in Table 3. In other words, although abnormal chr1 
was less frequent in the VMPT-VT arm, its negative impact was significant only in this subgroup, 
probably due to a negative effect of administering thalidomide to these patients. 
Smetana et al.
29
 analyzed several chromosomal abnormalities in 102 patients with relapsed MM 
treated with bortezomib- or thalidomide-based regimens. They suggested that bortezomib should be 
preferred to thalidomide in patients with relapsed and/or refractory MM carrying gain(1q), two or 
more cytogenetic abnormalities and/or del(17p). Our findings show the ability of VMP treatment to 
overcome the negative prognostic impact of abnormal chr1 in elderly patients with newly diagnosed 
MM, whereas the addition of thalidomide appears to have a negative effect on overall survival. 
Recently, the MRC Myeloma IX trial examined the role of thalidomide both as induction and 
maintenance therapy in patients with del(17p) (n=85). Thalidomide induction was associated with 
improved response rates, but not with improved overall survival, while, as maintenance therapy, it 
was associated with impaired survival
39
. In our cohort of del(17p) patients (n=55), thalidomide 
impaired overall survival, as shown by the univariate Cox analyses in Table 3. Moreover, Kaplan-
Meier analyses also highlighted a negative effect of thalidomide on overall survival in patients with 
del(17p) (13.5 months in the VMPT group versus 22.5 months in the VMP group, P=0.726), even 
though this was not statistically significant, probably because of the low frequency of del(17p) 
(14.6%), whereas thalidomide was observed to have a benefit in patients with a normal(17p) (42.3 
months in the VMPT arm versus 31.7 months in the VMP arm, P=0.061). The same trend was also 
confirmed by Kaplan-Meier analysis for progression-free survival [del(17p) patients: 16.8 months 
in the VMPT arm versus 19.5 months in the VMP arm, P=0.329; normal(17p) patients: 34.5 months 
in the VMPT arm versus 23.0 months in the VMP arm, P<0.001). In our study, we could not 
distinguish between the effects of thalidomide as induction or maintenance therapy, because all the 
patients in the VMPT arm also received VT maintenance, whereas patients in the VMP arm did not 
receive thalidomide at all. The detrimental role of thalidomide on overall survival was also 
evaluated in the whole series of patients in the MRC Myeloma IX trial by Brioli et al.,
40
 who 
underlined its negative effect on high-risk patients. Some authors suggest, instead, that thalidomide 
maintenance is more beneficial in high-risk disease.
41
 We did not observe any significant difference 
comparing the high-risk and the standard-risk groups, confirming the benefit of bortezomib 
administration in high-risk patients independently of thalidomide administration. 
The prognostic impact of plasma cell immunophenotype has been broadly investigated by several 
authors.
3,4,7
 More recently, CD19 expression on MM plasma cells has been studied and shown to be 
an adverse prognostic marker,
5,7
 while CD117 was found to be associated with a favorable 
outcome.
3
 In our study, we did not observe any association between clinical outcome and the single 
expression of CD45, CD20, CD117, or CD56. Mateo et al.
3
 published the results of an extensive 
study on 685 newly diagnosed MM patients entered into the GEM 2000 protocol. Their findings 





 patients were characterized by a shorter overall survival, but not 
progression-free survival. When the analysis was carried out in the two therapeutic arms separately, 
this combination of antigens only had a negative influence in the VMP arm, suggesting that 
treatment with thalidomide may overcome its adverse impact. 
Recently, it has been argued that the prognostic impact of genetic lesions is modulated over time by 
changes in the myeloma microenvironment and/or by interactions with new-onset cytogenetic 
abnormalities.
42
 For instance, MAF translocations [including t(14;16) and t(14;20)] are associated 
with a poor prognosis in MM whereas t(14;20) was not linked to disease progression in patients 
with monoclonal gammopathy of undetermined significance or smoldering MM.
43,44
 Time 
dependency of prognostic features was also highlighted by Barlogie et al.
45–47
 In recent years, the 
survival of MM patients has been extended from 5 to 10 years or more as a result of autotransplant-
supported high-dose melphalan treatment.
48,49
 This longer follow-up leads to biphasic or triphasic 
patterns in Kaplan-Meier curves, suggesting that several parameters might govern different time 
segments of survival outcomes.
46
 Cytogenetic abnormalities detected by gene expression 
profiling
45
, lactate dehydrogenase concentration and calcium levels
46
, as well as complete 
response
47
 have already been described as time-dependent variables. These observations support our 






In the multivariate Cox analysis on the whole series of patients, the protective role of thalidomide 




 expression were 
independent predictors for overall survival. 
In summary, our findings suggest that abnormal chr1 is an adverse prognostic factor for both overall 





 BMPC immunophenotype also has an adverse impact 
on overall survival; however, this antigen combination is rare with respect to abnormal chr1, which 
affects a large cluster of patients with a major impact on overall survival, as revealed by Cox 
multivariate analysis. Other genetic abnormalities did not have any impact on overall or 
progression-free survival, probably due to the administration of bortezomib. However, treatment 
with thalidomide, even when associated with bortezomib, seems to have a negative effect on 





 or advanced ISS stage. 
Our study is a retrospective and explorative study aimed at better understanding the effect of 
abnormal chr1 on elderly MM patients treated with novel agents and our results highlight a complex 
picture of multiple interactions among therapy, risk predictors and time. Although our results need 
to be confirmed in larger, prospective studies, they may help in the design of future clinical trials. 
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